[ Inside the business ]

DVA stock analysis

DVA · Davita Inc.

Services-misc health and allied services, nec. Growing 5%.

Watch: growth that has stopped speeding up.

The future, in 7 questions

Priced in: 0.3× sales in 5 yrs. Evidence: sales +5% · 15¢ profit/$1.

01 What's priced in?0.3× sales in 5 yrs
Sales now$14.2B
Needed in 5 yrs$4.1B
02 Is the wave rising?No Radar technology matched

Not among the companies mentioning Radar's technologies most.

03 Will customers keep buying?Sales +5%, steady
No customer over 10%
Sales +5%, steady
04 Is it scarce?No
PricingBacklogPrepaidSell-outTight
05 More profit per sale?Keeps 15¢ per $1
'21'22'23'24'2515¢
06 Can it fund itself?Pays its own way
05 yrsself-funded
Shares −9.8%/yrDebt $0
07 What could break it?3 to watch
  • Growth slowing
  • Insiders sold $123M outside pre-set plans
  • Moves strongly with the S&P 500

From SEC filings, price and Radar. Not advice.

The record

Early signals

Growth slowing.

Sales growth +6%, +5%, then +5% vs. a year ago.

What could go wrong

Few warning signs.

It has moved 1.0× the market. In the 2018 q4 selloff it fell 28% while the market fell 14%. Debt is covered by cash.

Speculative check

Self-funding.

Passes every condition: profitable, cash-generating and financially sound.

What they sell

85% U. S. Dialysis And Related Lab Services.

U. S. Dialysis And Related Lab Services 85% · Other Operating Segment 15% (latest quarter)

Where each dollar goes

Not available.

Cost lines aren't reported in a comparable form.

Its market

1.8× the economy.

The government expects its industry, ambulatory healthcare services, to grow 3.6% a year to 2035, vs. 2.0% for the whole economy.

Market size and share

Your call.

There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.

Life cycle

Maturity.

It earns cash, still invests, and pays back more than it borrows.

Earnings quality

Can't score.

Not available: some of the eight inputs aren't in the company's structured filings (common for banks, insurers and companies without a cost of goods line).

Competitive advantage

9 of 9 years.

Returns beat its 6.5% cost of capital in 9 of the last 9 years.

Future bets

4% on equipment.

$577M a year on equipment and buildings.

All figures from Davita Inc.'s SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.